卡培他滨联合顺铂一线治疗晚期食管癌的临床观察

Clinical observation of capecitabine plus cisplatin as first-line chemotherapy in advanced esophageal cancer

目的：观察卡培他滨联合顺铂一线治疗晚期食管癌的近期疗效和不良反应。方法：18例Ⅳ期食管癌患者，用卡培他滨1250mg／（m^2·d），每日分2次口服，第1～14d；顺铂20mg／次，静脉滴注，第1～5d（或40mg／次，静脉滴注，第1～3d）；21d为1周期，至少应用2周期。结果：共治疗18例，其中完全缓解1例，部分缓解9例，总有效率为55．56％。主要不良反应是骨髓抑制和消化道反应。结论：卡培他滨联合顺铂一线治疗晚期食管癌可获得较高的疗效，不良反应轻，是一种较好的化疗方案。

Objective To evaluate the efficacy of capecitabine and clsplatln as first-line chemotherapy in advanced esophageal cancer. Methods Eighteen patients with advanced esophageal cancer received oral capecitabine 1250 mg/（m^2 · d） for the first 14 days and cisplatin 20 mg, introvenous drip for the first 5 days or cisplatin 40 mg intravenous drip for the first 3 days. Another cycle was repeated after 7 days＇ rest, and each patient received 2 cycles at least. Results One patient achieved complete response and 9 patients achieved partial response with an overall response rate of 55.56%. The dose-limited toxicity was leukocytopenia and other adverse effects were mild. Conclusion Capecitabine plus cisplatin is effective as the first-line chemotherapy for advanced esophageal cancer. The adverse effects are mild and tolerable.